Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis

被引:1
|
作者
Bonnett, Shilah [1 ]
Jee, Jo-Ann [1 ]
Chettiar, Somsundaram [1 ]
Ovechkina, Yulia [1 ]
Korkegian, Aaron [1 ]
Greve, Eric [2 ]
Odingo, Joshua [1 ]
Parish, Tanya [1 ,2 ]
机构
[1] TB Discovery Res Infect Dis Res Inst, Seattle, WA 98102 USA
[2] Seattle Childrens Res Inst, Ctr Global Infect Dis Res, Seattle, WA 98105 USA
来源
MICROBIOLOGY SPECTRUM | 2023年 / 11卷 / 01期
基金
美国国家卫生研究院;
关键词
antitubercular; drug discovery; antibiotic; protein secretion; bactericidal activity; tuberculosis; DRUGS;
D O I
10.1128/spectrum.04974-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mycobacterium tuberculosis, the causative agent of tuberculosis, is a serious global health problem requiring the development of new therapeutics. We previously ran a high-throughput screen and identified a series of compounds with antitubercular activity. We identified an amino-benzothiazole scaffold from a whole-cell screen against recombinant Mycobacterium tuberculosis under expressing the essential signal peptidase LepB. The seed molecule had 2-fold higher activity against the LepB hypomorph. Through a combination of purchase and chemical synthesis, we explored the structure-activity relationship for this series; 34 analogs were tested for antitubercular activity and for cytotoxicity against eukaryotic cells. We identified molecules with improved potency and reduced cytotoxicity. However, molecules did not appear to target LepB directly and did not inhibit protein secretion. Key compounds showed good permeability, low protein binding, and lack of CYP inhibition, but metabolic stability was poor with short half-lives. The seed molecule showed good bactericidal activity against both replicating and nonreplicating bacteria, as well as potency against intracellular M. tuberculosis in murine macrophages. Overall, the microbiological properties of the series are attractive if metabolic stability can be improved, and identification of the target could assist in the development of this series.IMPORTANCE Mycobacterium tuberculosis, the causative agent of tuberculosis, is a serious global health problem requiring the development of new therapeutics. We previously ran a high-throughput screen and identified a series of compounds with antitubercular activity. In this paper, we test analogs of our hit molecules for activity against M. tuberculosis, as well as for activity against eukaryotic cells. We identified molecules with improved selectivity. Our molecules killed both replicating and nonreplicating bacteria but did not work by targeting protein secretion.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] In vitro activity of ofloxacin against Mycobacterium tuberculosis
    Yu, MC
    Suo, J
    Lin, TP
    Luh, KT
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1997, 96 (01) : 13 - 16
  • [42] In vitro activity of Fluoroquinolones against Mycobacterium tuberculosis
    Sulochana, S
    Rahman, F
    Paramasivan, CN
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (02) : 169 - 173
  • [43] Synthesis of Norfijimycin A with Activity against Mycobacterium tuberculosis
    Stoye, Alexander
    Nagalingam, Gayathri
    Britton, Warwick J.
    Payne, Richard J.
    AUSTRALIAN JOURNAL OF CHEMISTRY, 2017, 70 (02) : 229 - 232
  • [44] ACTIVITY OF AMIKACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS
    GARCIARODRIGUEZ, JA
    MARTINLUENGO, F
    SAENZGONZALEZ, MC
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1978, 4 (03) : 293 - 294
  • [45] Compounds with Potential Activity against Mycobacterium tuberculosis
    Emani, C. Sao
    Williams, M. J.
    Wiid, I. J.
    Baker, B.
    Carolis, C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)
  • [46] BACTERICIDAL ACTION OF PENICILLIN + PENICILLIN-ISONIAZID COMBINATIONS AGAINST MYCOBACTERIUM TUBERCULOSIS
    VAICHULIS, EMK
    VICHER, EE
    NOVAK, MV
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1964, 90 (03): : 458 - &
  • [47] Determination of minimum bactericidal concentration, in single or combination drugs, against Mycobacterium tuberculosis
    Santos, Nathally C. de S.
    Scodro, Regiane B. de L.
    Leal, Dayane C. B.
    do Prado, Silvia M. T.
    Micheletti, Daniela F.
    Sampiron, Eloisa G.
    Costacurta, Giovana F.
    de Almeida, Aryadne L.
    da Silva, Liliani A. F.
    Ieque, Andressa L.
    Lopes, Luciana D. G.
    de Padua, Rubia A. F.
    Siqueira, Vera L. D.
    Caleffi-Ferracioli, Katiany R.
    Cardoso, Rosilene F.
    FUTURE MICROBIOLOGY, 2020, 15 (02) : 107 - 114
  • [48] Micrococcin P1-A bactericidal thiopeptide active against Mycobacterium tuberculosis
    Degiacomi, Giulia
    Personne, Yoann
    Mondesert, Guillaume
    Ge, Xueliang
    Mandava, Chandra Sekhar
    Hartkoorn, Ruben C.
    Boldrin, Francesca
    Goel, Pavitra
    Peisker, Kristin
    Benjak, Andrej
    Barrio, Maria Belen
    Ventura, Marcello
    Brown, Amanda C.
    Leblanc, Veronique
    Bauer, Armin
    Sanyal, Suparna
    Cole, Stewart T.
    Lagrange, Sophie
    Parish, Tanya
    Manganelli, Riccardo
    TUBERCULOSIS, 2016, 100 : 95 - 101
  • [49] In vitro bactericidal activities of two novel dihydropyridine derivatives against Mycobacterium tuberculosis
    Zandhaghighi, Mehdi
    Hadizadeh, Farzin
    Soleimanpour, Saman
    Meshkat, Zahra
    Rezaee, Seyed Abdolrahim
    Derakhshan, Mohammad
    Ghazvini, Kiarash
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2017, 11 (06): : 453 - 458
  • [50] The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
    Pullan, Steven T.
    Allnutt, Jon C.
    Devine, Rebecca
    Hatch, Kim A.
    Jeeves, Rose E.
    Hendon-Dunn, Charlotte L.
    Marsh, Philip D.
    Bacon, Joanna
    BMC INFECTIOUS DISEASES, 2016, 16